- Mead Johnson expands board by one and appoints a former Ernst & Young vice chairman as a director
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- Bristol-Myers Squibb sells off diabetes business
- FDA advisory committee recommends approval for Bristol-Myers Squibb's, AstraZeneca's metreleptin in generalized lipodystrophy
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
GLENVIEW, Ill. — Mead Johnson Nutrition on Friday announced that the company's president and CEO, Steve Golsby, will retire by the 2013 annual meeting of stockholders. Mead Johnson's board selected Kasper Jakobsen, EVP and COO, to serve as CEO-elect.
Jakobsen is expected to succeed Golsby as Mead Johnson Nutrition president and CEO upon Golsby’s retirement, the company said. Jakobsen will continue in his role as COO, and the current senior leadership structure and reporting relationships will remain in effect.
"As Steve’s replacement, Kasper Jakobsen has the confidence of the full Board, reflecting his experience as a 14-year veteran of Mead Johnson, including operational leadership responsibility for the businesses in Asia, North America and Latin America prior to becoming executive vice president and chief operating officer earlier this year," Mead Johnson chairman Jim Cornelius said.